

**Louisiana Medicaid**  
**Enzyme Replacement Therapy (ERT)**  
**For Treatment of Mucopolysaccharidosis (MPS)**

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request clinical authorization for the following enzyme replacement therapy (ERT) agents used for the treatment of mucopolysaccharidosis (MPS).

Additional Point-of-Sale edits may apply.

*These agents have **Black Box Warnings**. Please refer to individual prescribing information for details.*

**Approval criteria for specific agents:**

**Laronidase (Aldurazyme™)**

- The recipient is 6 months of age or older on the date of the request; **AND**
- The recipient has a diagnosis of mucopolysaccharidosis I (MPS I) with one of the following phenotypes:
  - Hurler form (severe MPS I); **OR**
  - Hurler-Scheie form (attenuated MPS I); **OR**
  - Scheie form (attenuated MPS I) with moderate to severe symptoms; **AND**
- The diagnosis of MPS I is confirmed by both of the following [Include dates and results on request]:
  - Elevated urine glycosaminoglycans (GAGs); **AND**
  - Deficiency in the alpha-L-iduronidase enzyme; **AND**
- The medication is being prescribed by, or the request states that the medication is being prescribed in consultation with, a provider experienced in the treatment of lysosomal storage diseases (LSDs), such as geneticist or endocrinologist; **AND**
- The recipient has at least **ONE** clinical manifestation known to respond to ERT (e.g., pulmonary, cardiac or musculoskeletal dysfunction); **AND**
- By submitting the authorization request, the prescriber attests to the following:
  - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
  - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
  - The recipient has no concomitant drug therapies or disease states that limit the use of the requested agent; **AND**
  - The medication will not be used in combination with any medication that is contraindicated or not recommended per FDA labeling.

### **Reauthorization Criteria for laronidase (Aldurazyme™)**

- The recipient continues to meet all initial approval criteria; **AND**
- The recipient demonstrates a positive clinical response from baseline (i.e., improvement in respiratory function, cardiac function, walking ability or quality of life) and details of improvement are **stated on the request**.

**Duration of initial approval: 6 months**

**Duration of reauthorization approval: 12 months**

### **Idursulfase (Elaprase®)**

- The recipient is 16 months of age or older on the date of the request; **AND**
- The recipient has a diagnosis of Hunter syndrome (Mucopolysaccharidosis II, MPS II) confirmed by both of the following [Include dates and results on request]:
  - Elevated urine glycosaminoglycans (GAGs); **AND**
  - Deficiency in the iduronate 2-sulfatase enzyme; **AND**
- The medication is being prescribed by or in consultation with a provider experienced in the treatment of lysosomal storage diseases (LSDs); **AND**
- The recipient has at least **ONE** clinical manifestation known to respond to ERT (e.g., pulmonary, cardiac or musculoskeletal dysfunction); **AND**
- By submitting the authorization request, the prescriber attests to the following:
  - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
  - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
  - The recipient has no concomitant drug therapies or disease states that limit the use of the requested agent; **AND**
  - The medication will not be used in combination with any medication that is contraindicated or not recommended per FDA labeling.

### **Reauthorization Criteria for idursulfase (Elaprase®)**

- The recipient continues to meet all initial approval criteria; **AND**
- The recipient demonstrates a positive clinical response from baseline (i.e., improvement in respiratory function, cardiac function, walking ability or quality of life) and details of improvement are **stated on the request**.

**Duration of initial approval: 6 months**

**Duration of reauthorization approval: 12 months**

### **Elosulfase Alfa (Vimizim®)**

- The recipient is 5 years of age or older on the date of the request; **AND**
- The recipient has a diagnosis of Morquio A syndrome (Mucopolysaccharidosis IVA, MPS IVA) confirmed by both of the following [Include dates and results on request]:
  - Elevated urine glycosaminoglycans (GAGs); **AND**
  - Deficiency in the N-acetyl-galactosamine-6-sulfate sulfatase (GALNS) enzyme; **AND**
- The medication is being prescribed by or in consultation with a provider experienced in the treatment of lysosomal storage diseases (LSDs); **AND**
- The recipient has at least **ONE** clinical manifestation known to respond to ERT (e.g., pulmonary, cardiac or musculoskeletal dysfunction); **AND**
- By submitting the authorization request, the prescriber attests to the following:
  - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
  - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
  - The recipient has no concomitant drug therapies or disease states that limit the use of the requested agent; **AND**
  - The medication will not be used in combination with any medication that is contraindicated or not recommended per FDA labeling.

### **Reauthorization Criteria for elosulfase alfa (Vimizim®)**

- The recipient continues to meet all initial approval criteria; **AND**
- The recipient demonstrates a positive clinical response from baseline (i.e., improvement in respiratory function, cardiac function, walking ability or quality of life) and details of improvement are **stated on the request**.

**Duration of initial approval: 6 months**

**Duration of reauthorization approval: 12 months**

### **Galsulfase (Naglazyme®)**

- The recipient is 5 years of age or older on the date of the request; **AND**
- The recipient has a diagnosis of Maroteaux-Lamy syndrome (Mucopolysaccharidosis VI, MPS VI) confirmed by both of the following [Include dates and results on request]:
  - Elevated urine glycosaminoglycans (GAGs); **AND**
  - Deficiency in the N-acetylgalactosamine 4-sulfatase (arylsulfatase B) enzyme; **AND**
- The medication is being prescribed by or in consultation with a provider experienced in the treatment of lysosomal storage diseases (LSDs); **AND**
- The recipient has at least **ONE** clinical manifestation known to respond to ERT (e.g., pulmonary, cardiac or musculoskeletal dysfunction); **AND**

- By submitting the authorization request, the prescriber attests to the following:
  - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
  - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
  - The recipient has no concomitant drug therapies or disease states that limit the use of the requested agent; **AND**
  - The medication will not be used in combination with any medication that is contraindicated or not recommended per FDA labeling.

#### **Reauthorization Criteria for galsulfase (Naglazyme®)**

- The recipient continues to meet all initial approval criteria; **AND**
- The recipient demonstrates a positive clinical response from baseline (i.e., improvement in respiratory function, cardiac function, walking ability or quality of life) and details of improvement are **stated on the request**.

#### **Duration of initial approval: 6 months**

#### **Duration of reauthorization approval: 12 months**

#### **Vestronidase Alfa-vjbk (Mepsevii™)**

- The recipient is 5 months of age or older on the date of the request; **AND**
- The recipient has a diagnosis of Sly syndrome (Mucopolysaccharidosis VII, MPS VII) confirmed by both of the following [Include dates and results on request]:
  - Elevated urine glycosaminoglycans (GAGs); **AND**
  - Deficiency in the  $\beta$ -glucuronidase (GUS) enzyme; **AND**
- The medication is being prescribed by or in consultation with a provider experienced in the treatment of lysosomal storage diseases (LSDs); **AND**
- The recipient has at least **ONE** clinical manifestation known to respond to ERT (e.g., pulmonary, cardiac or musculoskeletal dysfunction); **AND**
- By submitting the authorization request, the prescriber attests to the following:
  - The prescribing information for the requested medication has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**
  - All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended; **AND**
  - The recipient has no concomitant drug therapies or disease states that limit the use of the requested agent; **AND**

- The medication will not be used in combination with any medication that is contraindicated or not recommended per FDA labeling.

#### **Reauthorization Criteria for vestronidase alfa-vjbk (Mepsevii™)**

- The recipient continues to meet all initial approval criteria; **AND**
- The recipient demonstrates a positive clinical response from baseline (i.e., improvement in respiratory function, cardiac function, walking ability or quality of life) and details of improvement are **stated on the request**.

**Duration of initial approval: 6 months**

**Duration of reauthorization approval: 12 months**

#### **References**

Aldurazyme™ (laronidase) [package insert]. Cambridge, MA: Genzyme Corporation; 2013.  
<http://products.sanofi.us/Aldurazyme/aldurazyme.pdf>

Clarke LA. Mucopolysaccharidosis Type I. 2002 Oct 31 [Updated 2016 Feb 11]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1162/>

Elaprase® (idursulfase) [package insert]. Lexington, MA: Shire Human Genetic Therapies, Inc; 2018.  
[http://pi.shirecontent.com/PI/PDFs/Elaprase\\_USA\\_ENG.pdf](http://pi.shirecontent.com/PI/PDFs/Elaprase_USA_ENG.pdf)

Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. *Genet Mol Biol*. 2010;33(4):589–604. doi:10.1590/S1415-47572010005000093

Hendriksz CJ, Berger KI, Giugliani R, et al. International guidelines for the management and treatment of Morquio A syndrome. *Am J Med Genet A*. 2015;167A(1):11–25. doi:10.1002/ajmg.a.36833

Martins et al. Guidelines for the Management of Mucopolysaccharidosis Type I. *J Peds*. Vol. 155, No. 4, Suppl. 2, pp S32-S46. 2009 October. Available from [https://www.jpeds.com/article/S0022-3476\(09\)00675-1/pdf](https://www.jpeds.com/article/S0022-3476(09)00675-1/pdf)

Mepsevii™ (vestronidase alfa-vjbk) [package insert]. Novato, CA: Ultragenyx Pharmaceutical Inc; 2017. [https://www.ultragenyx.com/file.cfm/96/docs/FINAL\\_Mepsevii\(vestronidase\\_alfa-vjbk\)\\_USPI.pdf](https://www.ultragenyx.com/file.cfm/96/docs/FINAL_Mepsevii(vestronidase_alfa-vjbk)_USPI.pdf)

Montaño AM, Lock-Hock N, Steiner RD, et al Clinical course of sly syndrome (mucopolysaccharidosis type VII) *Journal of Medical Genetics* 2016;53:403-418.

Naglazyme® (galsulfase) [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2013.  
<https://www.naglazyme.com/hcp/>

Scarpa M. Mucopolysaccharidosis Type II. 2007 Nov 6 [Updated 2018 Oct 4]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1274/>

Vimizim® (elosulfase alfa) [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2014.  
<https://vimizim.com/hcp/wp-content/uploads/2018/03/Prescribing-Information.pdf>

Revision	Date
Policy created	March 2020